Exonate Renames to Foventa Therapeutics
Exonate, a company focused on eye diseases, has renamed itself Foventa Therapeutics. The new name reflects the company's transition to focus on clinical development for non-proliferative diabetic retinopathy.
Exonate has officially changed its name to Foventa Therapeutics, the company announced. The rebranding signifies a strategic shift toward concentrating on the clinical development of treatments for non-proliferative diabetic retinopathy.
The company's research centers on FOV407, a compound that has demonstrated a significant ability to suppress harmful vascular leakage in patients' eyes during earlier clinical trials. This leakage is a critical factor in the progression of vision loss associated with various eye conditions.
By targeting this specific mechanism, Foventa Therapeutics aims to advance novel therapies designed to slow or prevent disease progression. The name 'Foventa' is inspired by the fovea, a central pit in the eye responsible for sharpest vision, underscoring the company's commitment to preserving sight.
The transition to Foventa Therapeutics marks the company's progression into later-stage clinical development. The company intends to move its promising candidates through further clinical trials with the goal of bringing new treatment options to patients suffering from debilitating eye diseases.